References
- Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136–139.
- Menter A, Cordoro KM, Davis DMR, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. J Am Acad Dermatol. 2020;82(1):161–201.
- Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016;2(4):151–153.
- Feldman SR, Zhao Y, Shi L, et al. Economic and comorbidity burden among patients with moderate-to-severe psoriasis. J Manag Care Spec Pharm. 2015;21(10):874–888.
- Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States: a systematic review. JAMA Dermatol. 2015;151(6):651–658.
- Brezinski EA, Armstrong AW. Off-label biologic regimens in psoriasis: a systematic review of efficacy and safety of dose escalation, reduction, and interrupted biologic therapy. PLoS One. 2012;7(4):e33486.
- Cassano N, Loconsole F, Miracapillo A, et al. Treatment of psoriasis with different dosage regimens of etanercept: preliminary results from the Tαranta Plastic Study Group. Int J Immunopathol Pharmacol. 2010;23(3):797–802.
- Bagel J. Parting Words from Jerry Bagel, MD. The psoriasis treatment landscape has changed dramatically during this editor’s tenure. 2019. [cited 2020]. https://practicaldermatology.com/articles/2019-aug/parting-words-from-jerry-bagel-md.